Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Glioblastoma 115Gliosarcoma 53Brain Neoplasms 53Glioma 47Central Nervous System Neoplasms 30Astrocytoma 29Melanoma 26Oligodendroglioma 14Neuroblastoma 10Neoplasm Metastasis 9Recurrence 7Ependymoma 7Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Skin Neoplasms 5Sarcoma, Ewing 5Lymphoma 5Breast Neoplasms 5Spinal Cord Neoplasms 4Somatostatinoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Lung Neoplasms 3Gastrinoma 3Carcinoma, Islet Cell 3Uveal Melanoma 2Rhabdomyosarcoma 2

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × Temozolomide × Clear all
NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT01143402 2017-07-26

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled 8 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡